Biolog Expands Line of Phenotype MicroArrays(TM) for Medically Important Microbes

Apr 19, 2001, 01:00 ET from Biolog, Inc.

    HAYWARD, Calif., April 19 /PRNewswire/ -- Biolog, Inc., a biotechnology
 company pioneering powerful new tools for cell-based analysis, announced today
 the release of protocols using Phenotype MicroArrays(TM) (PMs) for a range of
 medically and commercially important microbial species, including microbes
 targeted for antibiotic drug discovery.
     Phenotype MicroArrays (PMs) are rapid cellular assays that provide global
 cellular analysis as well as specific information about cell function.
 Designed to study a range of cell properties, or phenotypes, PMs enable
 scientists to quickly and efficiently determine how a genetic change or a drug
 lead affects living cells. This technology allows researchers to test
 hundreds to thousands of cell properties simultaneously, and has applications
 in determining gene function, validating and optimizing drug targets,
 analyzing a drug's mode of action, assessing toxicology, and basic cellular
 research.
     The new PMs are optimized for the study of Salmonella typhimurium, Vibrio
 spp., Pseudomonas aeruginosa, Burkholderia cepacia, Ralstonia solanacearum,
 Sinorhizobium meliloti, and Listeria monocytogenes. The pathogens Salmonella,
 Vibrio and Listeria can cause acute infections in humans. Pseudomonas
 aeruginosa and Burkholderia cepacia are common environmental bacteria
 responsible for persistent and serious infections in humans, including lung
 infections in cystic fibrosis patients, eye infections, bone infections, and
 septicemias. Pseudomonas aeruginosa is particularly problematic because it is
 highly resistant to antibiotic therapy. The microorganisms Ralstonia
 solanacearum, other Pseudomonads, Burkholderia species, and Sinorhizobium
 meliloti are important in agriculture because of their ability to cause or to
 benefit plants.
     PMs are expected to play an important role in genomics-based
 anti-microbial drug development. Researchers at universities and
 pharmaceutical/biotech companies can use PMs to understand the biological
 differences between harmless or beneficial strains of microbes and dangerous
 pathogenic strains of the same species. PMs allow scientist to rapidly
 determine the function of genes thought to be involved in pathogenicity. The
 gene of interest is altered, then PMs are used to compare the control cell
 line with the genetically changed cells to see how the cells' physiology has
 changed.
     PMs also provide a comprehensive assay for the effect of drug leads
 (e.g., antibiotics) on cells. To assess a drug lead's efficacy with an
 infectious microorganism, the cells are exposed to the drug and PMs
 fingerprint the physiological effects of the drug on the cell. This use allows
 rapid screening of chemical libraries, mode of action assessment, drug
 interactions, and side effects. By using PM technology, researchers gain
 valuable basic insights into disease processes, validate potential new targets
 for antibiotics, and rapidly characterize drug leads.
     "Since its introduction May 2000, PM technology has received strong
 interest from researchers around the globe," stated Timothy Mullane, president
 and CEO of Biolog. "With our ability to provide important answers in
 antibacterial and antifungal research, we are currently directing our
 commercial efforts toward the establishment of collaborations with
 pharmaceutical and biotech companies in accelerating development of infectious
 disease therapies. We are also beginning to develop PMs for mammalian cells,
 which should provide powerful tools for researchers working on drugs to treat
 diseases such as cancer and diabetes."
     Listeria monocytogenes is the first gram-positive bacterial species
 released for PM analysis, and Biolog will soon be releasing PM protocols for
 other important gram-positive genera including Staphylococcus, Streptococcus,
 and Enterococcus. Also in development are PMs and protocols for a wide variety
 of yeasts and filamentous fungi, including pathogens such as Candida albicans
 and Ustilago maydis. Biolog is the recipient of a Phase II SBIR Award from
 NIH-NIGMS. The award is funding the development of PMs covering about 2000
 phenotypes of the bacterium Escherichia coli and the yeast Saccharomyces
 cerevisiae. However, the same PMs developed for these species can in fact be
 used with many other important species.
     Biolog is a pioneer in the development of powerful cellular analysis tools
 for solving critical problems in clinical, pharmaceutical, and biotechnology
 research and drug development. The company's Phenotype MicroArray technology
 and OmniLog PM System for such applications as determining gene function,
 validating and optimizing drug targets, and assessing cellular toxicology.
 Further information can be obtained at the company's website, www.biolog.com.
 
 

SOURCE Biolog, Inc.
    HAYWARD, Calif., April 19 /PRNewswire/ -- Biolog, Inc., a biotechnology
 company pioneering powerful new tools for cell-based analysis, announced today
 the release of protocols using Phenotype MicroArrays(TM) (PMs) for a range of
 medically and commercially important microbial species, including microbes
 targeted for antibiotic drug discovery.
     Phenotype MicroArrays (PMs) are rapid cellular assays that provide global
 cellular analysis as well as specific information about cell function.
 Designed to study a range of cell properties, or phenotypes, PMs enable
 scientists to quickly and efficiently determine how a genetic change or a drug
 lead affects living cells. This technology allows researchers to test
 hundreds to thousands of cell properties simultaneously, and has applications
 in determining gene function, validating and optimizing drug targets,
 analyzing a drug's mode of action, assessing toxicology, and basic cellular
 research.
     The new PMs are optimized for the study of Salmonella typhimurium, Vibrio
 spp., Pseudomonas aeruginosa, Burkholderia cepacia, Ralstonia solanacearum,
 Sinorhizobium meliloti, and Listeria monocytogenes. The pathogens Salmonella,
 Vibrio and Listeria can cause acute infections in humans. Pseudomonas
 aeruginosa and Burkholderia cepacia are common environmental bacteria
 responsible for persistent and serious infections in humans, including lung
 infections in cystic fibrosis patients, eye infections, bone infections, and
 septicemias. Pseudomonas aeruginosa is particularly problematic because it is
 highly resistant to antibiotic therapy. The microorganisms Ralstonia
 solanacearum, other Pseudomonads, Burkholderia species, and Sinorhizobium
 meliloti are important in agriculture because of their ability to cause or to
 benefit plants.
     PMs are expected to play an important role in genomics-based
 anti-microbial drug development. Researchers at universities and
 pharmaceutical/biotech companies can use PMs to understand the biological
 differences between harmless or beneficial strains of microbes and dangerous
 pathogenic strains of the same species. PMs allow scientist to rapidly
 determine the function of genes thought to be involved in pathogenicity. The
 gene of interest is altered, then PMs are used to compare the control cell
 line with the genetically changed cells to see how the cells' physiology has
 changed.
     PMs also provide a comprehensive assay for the effect of drug leads
 (e.g., antibiotics) on cells. To assess a drug lead's efficacy with an
 infectious microorganism, the cells are exposed to the drug and PMs
 fingerprint the physiological effects of the drug on the cell. This use allows
 rapid screening of chemical libraries, mode of action assessment, drug
 interactions, and side effects. By using PM technology, researchers gain
 valuable basic insights into disease processes, validate potential new targets
 for antibiotics, and rapidly characterize drug leads.
     "Since its introduction May 2000, PM technology has received strong
 interest from researchers around the globe," stated Timothy Mullane, president
 and CEO of Biolog. "With our ability to provide important answers in
 antibacterial and antifungal research, we are currently directing our
 commercial efforts toward the establishment of collaborations with
 pharmaceutical and biotech companies in accelerating development of infectious
 disease therapies. We are also beginning to develop PMs for mammalian cells,
 which should provide powerful tools for researchers working on drugs to treat
 diseases such as cancer and diabetes."
     Listeria monocytogenes is the first gram-positive bacterial species
 released for PM analysis, and Biolog will soon be releasing PM protocols for
 other important gram-positive genera including Staphylococcus, Streptococcus,
 and Enterococcus. Also in development are PMs and protocols for a wide variety
 of yeasts and filamentous fungi, including pathogens such as Candida albicans
 and Ustilago maydis. Biolog is the recipient of a Phase II SBIR Award from
 NIH-NIGMS. The award is funding the development of PMs covering about 2000
 phenotypes of the bacterium Escherichia coli and the yeast Saccharomyces
 cerevisiae. However, the same PMs developed for these species can in fact be
 used with many other important species.
     Biolog is a pioneer in the development of powerful cellular analysis tools
 for solving critical problems in clinical, pharmaceutical, and biotechnology
 research and drug development. The company's Phenotype MicroArray technology
 and OmniLog PM System for such applications as determining gene function,
 validating and optimizing drug targets, and assessing cellular toxicology.
 Further information can be obtained at the company's website, www.biolog.com.
 
 SOURCE  Biolog, Inc.